# EDGAR Filing Document

**Accession Number:** 0001869105
**File Stem:** 0001193125-26-187049
**Filing Date:** 2026-4
**Character Count:** 1292
**Document Hash:** b365fddbe9082d902647194c58ac2809
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-187049.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001193125-26-187049

**CONFORMED SUBMISSION TYPE**: ARS

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260428

**EFFECTIVENESS DATE**: 20260428

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BridgeBio Oncology Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001869105
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** ARS
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41955
- **FILM NUMBER:** 26907863

**BUSINESS ADDRESS:**
- **STREET 1:** 256 E. GRAND AVENUE, SUITE 104
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 857 702 0377

**MAIL ADDRESS:**
- **STREET 1:** 256 E. GRAND AVENUE, SUITE 104
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Helix Acquisition Corp. II
- **DATE OF NAME CHANGE:** 20210623

### Attached PDF Documents

**Attachment 1:** `d134712dars.pdf`

_No text found in this document._